Downgrades Archives - Page 163 of 277

1 minute read

Morgan Stanley Downgrades Principal Finl Gr to Underweight, Raises Price Target to $79

November 17, 6:09 AM

Morgan Stanley analyst Nigel Dally downgrades Principal Finl Gr (NASDAQ:PFG) from Equal-Weight to Underweight and raises the price target from $76 to $79.

PFG

1 minute read

Credit Suisse Downgrades Aveanna Healthcare Hldgs to Neutral, Lowers Price Target to $2

By Benzinga Newsdesk

November 17, 6:03 AM

Credit Suisse analyst A.J. Rice downgrades Aveanna Healthcare Hldgs (NASDAQ:AVAH) from Outperform to Neutral and lowers the price target from $5.5 to $2.

AVAH

1 minute read

Piper Sandler Downgrades Brigham Minerals to Neutral, Raises Price Target to $36

By Benzinga Newsdesk

November 17, 6:01 AM

Piper Sandler analyst Mark Lear downgrades Brigham Minerals (NYSE:MNRL) from Overweight to Neutral and raises the price target from $34 to $36.

MNRL

1 minute read

Citigroup Downgrades HUYA to Sell, Lowers Price Target to $3

By Benzinga Newsdesk

November 16, 3:27 PM

Citigroup analyst Brian Gong downgrades HUYA (NYSE:HUYA) from Neutral to Sell and lowers the price target from $4 to $3.

HUYA

2 minute read

Security Software Analyst Downgrades Rapid7 On Dismal Q3 Performance

By Anusuya Lahiri

November 16, 2:34 PM

Keybanc analyst Michael Turits downgraded Rapid7, Inc (NASDAQ: RPD) from Overweight to Sect

PANW

1 minute read

Sidoti & Co. Downgrades McGrath RentCorp to Neutral, Announces $106 Price Target

By Benzinga Newsdesk

November 16, 9:56 AM

Sidoti & Co. analyst Marc Riddick downgrades McGrath RentCorp (NASDAQ:MGRC) from Buy to Neutral and announces $106 price target.

MGRC

1 minute read

Chardan Capital Downgrades Evelo Biosciences to Neutral, Announces $2.5 Price Target

By Benzinga Newsdesk

November 16, 9:27 AM

Chardan Capital analyst Keay Nakae downgrades Evelo Biosciences (NASDAQ:EVLO) from Buy to Neutral and announces $2.5 price target.

EVLO

1 minute read

B. Riley Securities Downgrades Spectrum Pharmaceuticals to Neutral, Lowers Price Target to $1

By Benzinga Newsdesk

November 16, 9:19 AM

B. Riley Securities analyst Mayank Mamtani downgrades Spectrum Pharmaceuticals (NASDAQ:SPPI) from Buy to Neutral and lowers the price target from $1.5 to $1.

SPPI